Live Breaking News & Updates on Biomed Media Contact
Stay updated with breaking news from Biomed media contact. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Q BioMed Engages Contract Sales Force with Deep VA and Oncology Experience prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Q BioMed Insider to Invest up to $30M in the Company Aedesius Holdings Ltd. (AedesiusOne), a privately held global disruption aggregator, enters Into $30M Securities Purchase Agreement with Q BioMed Up front investment of up to $20M with an optional $10M in 6 month warrants Proceeds may be used for deploying contract sales force, advancing pipeline, redeeming outstanding convertible debt and convertible preferred shares and acquiring later-stage asset(s) News provided by Share this article QBIO), announced today that it has signed a securities purchase agreement ( Transaction ) with Aedesius Holdings Ltd (AedesiusOne), a privately owned United Kingdom based healthcare and technology aggregator. AedesiusOne is run by Geoffrey Fatzinger, our Global Head of Regulatory Affairs. The agreement gives AedesiusOne the opportunity to buy approximately 43% of the outstanding QBIO shares for an aggregate of $30,000,000. The Transaction is structured as an initial inve ....
Q BioMed Updates Shareholders Technology partner, Mannin Research, receives new R&D funding for COVID project and Several Milestones Expected in 2021 News provided by Share this article Share this article NEW YORK, April 27, 2021 /PRNewswire/ Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders. In March 2021,it was announced that our technology partner, Mannin Research Inc. (Mannin), is receiving up to CAD$1.7 million in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the pre-clinical development of a therapeutic to treat Acute Respiratory Distress Syndrome in COVID-19. This funding adds to approximately $7 million granted in Europe, which together will fund 65-75 percent of every dollar incurred to advance the Acute Respiratory Distress Syndrome therapy for COVID patients as well as a portfolio of therapeutic assets for vascular ....
Share this article NEW YORK, Jan. 27, 2021 /PRNewswire/ Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration s Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B, a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. In preclinical studies, Uttroside-B was up to 10-times more potent against HCC cells than Sorafinib, the standard of care drug at the time. As an Orphan Drug, Uttroside-B may benefit from a seven-year market exclusively following marketing approval, grant funding for clinical trials that contribute to marketing approval, protocol assistance, and tax credits. Preclinical testing is now underway to support an FDA Investigational New Drug (IND) application expected this year. ....
NEW YORK, Jan. 26, 2021 /PRNewswire/ Q Biomed Inc. (OTCQB: QBIO), announces that it has received additional notices of patent allowances from both Canada and Japan for its Uttroside-B molecule intended to treat liver cancer. The patent titled Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. International and additional U.S. claims are currently under prosecution for the technology which addresses a severe unmet need for a safe and effective drug to treat HCC. ....